New Products

New Machine Learning Tool Can Predict Adverse Drug Effects

June 29, 2020

A new computer algorithm might be the next step toward accurate prediction of adverse drug reactions.

FDA OKs New Treatment for Seizures Associated with Dravet Syndrome

June 26, 2020

Officials with the FDA approved fenfluramine (Fintepla, Zogenix) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.

FDA Approves Treatment for Recurrent Diabetes Gastroparesis

June 23, 2020

The first and only one of its kind, metoclopramide nasal spray offers relief to often debilitating symptoms of the gastrointestinal disease.

Barhemsys (Amisulpride) for Postoperative Nausea and Vomiting

June 22, 2020

On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting.

FDA Clears First Prescription Game-Based Treatment Device for Children With ADHD

June 17, 2020

EndeavorRx (Akili Interactive), a prescription-only game-based device, is indicated for use in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.

FDA Approves Secukinumab for Treatment of Non-Radiographic Axial Spondyloarthritis

June 17, 2020

FDA approval for the secukinumab (Cosentyx, Novartis) for non-radiographic axial spondyloarthritis was based on results from the PREVENT trial, which showed significant reduction in disease activity.

FDA OKs FreeStyle Libre 2 System for Adults and Children With Diabetes

June 15, 2020

Abbott’s FreeStyle Libre 2 is an integrated continuous glucose monitoring system for adults and children ages 4 and older with diabetes.

FDA Approves Dolutegravir Tablets for Oral Suspension for Children With HIV

June 12, 2020

Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.

FDA OKs Antibiotic for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

June 08, 2020

Officials with the FDA have approved imipenem, cilastatin, and relebactam (Recarbrio, Merck) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia. 

FDA Approves Ixekizumab for Non-radiographic Axial Spondyloarthritis

June 03, 2020

Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.